This study assesses the cost-effectiveness of adding a sodium-glucose cotransporter 2 inhibitor versus switching to a glucagon-like peptide-1 receptor agonist in patients with diabetes on metformin and a dipeptidyl peptidase-4 inhibitor.
Julia F. Slejko, PhD
Advertisement
Articles by Julia F. Slejko, PhD
Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Plastic in Personal Care Products Tied to Skin Disease and Environmental Pollution, Review Finds
2
Delgocitinib Coverage Could Save Health Plans $88M Over 3 Years
3
Three Years on Baricitinib Preserved Hair Regrowth in Severe Alopecia Areata
4
First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD
5